Sign In
Buy HOLX
$76.01
+0 (+0%)
At Close: Jul 06, 2026
Hologic (HOLX) Q1 2022 Earnings Call Transcript
06:30am, Thursday, 03'rd Feb 2022 The Motley Fool
HOLX earnings call for the period ending December 31, 2021.
Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q1 2022 Results - Earnings Call Transcript
03:17am, Thursday, 03'rd Feb 2022 Seeking Alpha
Hologic (HOLX) Q1 Earnings and Revenues Surpass Estimates
10:45pm, Wednesday, 02'nd Feb 2022 Zacks Investment Research
Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q1 2022 Results - Earnings Call Transcript
10:17pm, Wednesday, 02'nd Feb 2022
Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q1 2022 Results - Earnings Call Transcript
Hologic Earnings, Revenue Beat in Q1 By Investing.com
09:20pm, Wednesday, 02'nd Feb 2022 Investing.com
Hologic Earnings, Revenue Beat in Q1
Hologic Non-GAAP EPS of $2.17 beats by $0.96, revenue of $1.47B beats by $260M (NASDAQ:HOLX)
09:12pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Hologic press release (HOLX): Q1 Non-GAAP EPS of $2.17 beats by $0.96.Revenue of $1.47B (-8.7% Y/Y) beats by $260M.Shares +5%.Q2 2022 Guidance: Revenue to range between $1.25-$1.3B vs
Hologic Announces Financial Results for First Quarter of Fiscal 2022
09:01pm, Wednesday, 02'nd Feb 2022 Business Wire
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic Announces Financial Results for First Quarter of Fiscal 2022
Hologic (HOLX) Q1 Earnings and Revenues Surpass Estimates
07:10pm, Wednesday, 02'nd Feb 2022
Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
12:33pm, Wednesday, 02'nd Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
LogicBio Phase 1/2 Study Of Genome Editing Therapy In Methylmalonic Acidemia Placed On Clinical Hold
L
Hologic Launches First-Ever National Advertising Campaign Featuring Mary J. Blige
12:00pm, Tuesday, 01'st Feb 2022 Kwhen FinanceMedical Products Stock Earnings on Feb 2: BSX, TMO & More
09:59am, Tuesday, 01'st Feb 2022
Medical Products companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BSX, TMO, HOLX and MCK are poised ahead of their earnings releases.
Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe
04:43pm, Monday, 31'st Jan 2022 Zacks Investment Research
Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
01:13pm, Monday, 31'st Jan 2022 Benzinga
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Johnson & Johnson (NYSE: JNJ) got the ball rolling on large-cap biopharma earnings, with
CVS Health (CVS) Hits a 52-Week High: What's Driving It?
04:04pm, Friday, 28'th Jan 2022 Zacks Investment Research
Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
03:38pm, Friday, 28'th Jan 2022 Zacks Investment Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
